1-20 of 43
Michael B. Atkins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma

Elaine Chang, Jiaxi Zhou, Chi Song, Haley Gittleman, Laura Fernandes, Chana Weinstock, Michael B. Atkins, Sundeep Agrawal, Rajeshwari Sridhara, Nicole Gormley, Shenghui Tang, Daniel L. Suzman, Laleh Amiri-Kordestani, Paul G. Kluetz, Richard Pazdur, Brian I. Rini, David F. McDermott, Meredith M. Regan
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3282–3286.
https://doi.org/10.1158/1078-0432.CCR-23-3719
Published: 01 August 2024
View article titled, A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma
Open the PDF for A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients

Thomas Denize, Opeyemi A. Jegede, Sayed Matar, Nourhan El Ahmar, Destiny J. West, Emily Walton, Aseman Sheshdeh Bagheri, Varunika Savla, Yasmin Nabil Laimon, Saurabh Gupta, Sai Vikram Vemula, David A. Braun, Kelly P. Burke, Paul J. Catalano, Gordon J. Freeman, Robert J. Motzer, Michael B. Atkins, David F. McDermott, Arlene H. Sharpe, Toni K. Choueiri, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 803–813.
https://doi.org/10.1158/1078-0432.CCR-23-2274
Published: 16 February 2024
View article titled, PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients
Open the PDF for PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients in another window
Includes: Supplementary data
Journal Articles

Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma

Thomas Denize, Yue Hou, Jean-Christophe Pignon, Emily Walton, Destiny J. West, Gordon J. Freeman, David A. Braun, Catherine J. Wu, Saurabh Gupta, Robert J. Motzer, Michael B. Atkins, David McDermott, Toni K. Choueiri, Sachet A. Shukla, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4045–4055.
https://doi.org/10.1158/1078-0432.CCR-22-0923
Published: 15 September 2022
View article titled, Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Open the PDF for Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K. Choueiri, Laurence Albiges, Michael B. Atkins, Ziad Bakouny, Gennady Bratslavsky, David A. Braun, Naomi B. Haas, John B.A.G. Haanen, A. Ari Hakimi, Michael A.S. Jewett, Eric Jonasch, William G. Kaelin, Jr, Payal Kapur, Chris Labaki, Bryan Lewis, David F. McDermott, Sumanta K. Pal, Kevin Pels, Susan Poteat, Thomas Powles, W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Hans J. Hammers
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 831–839.
https://doi.org/10.1158/1078-0432.CCR-21-3238
Published: 03 March 2022
View article titled, From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Open the PDF for From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit in another window
Journal Articles

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6687–6695.
https://doi.org/10.1158/1078-0432.CCR-21-2283
Published: 15 December 2021
View article titled, Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Open the PDF for Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial in another window
Includes: Supplementary data
Journal Articles

The State of Melanoma: Emergent Challenges and Opportunities

Michael B. Atkins, Clara Curiel-Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre-Ghiso, Maria S. Soengas, Ashani T. Weeraratna, Keith T. Flaherty, Meenhard Herlyn, Jeffrey A. Sosman, Hussein A. Tawbi, Anna C. Pavlick, Pamela B. Cassidy, Sunandana Chandra, Paul B. Chapman, Adil Daud, Zeynep Eroglu, Laura K. Ferris, Bernard A. Fox, Jeffrey E. Gershenwald, Geoffrey T. Gibney, Douglas Grossman, Brent A. Hanks, Douglas Hanniford, Eva Hernando, Joanne M. Jeter, Douglas B. Johnson, Samir N. Khleif, John M. Kirkwood, Sancy A. Leachman, Darren Mays, Kelly C. Nelson, Vernon K. Sondak, Ryan J. Sullivan, Glenn Merlino
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2678–2697.
https://doi.org/10.1158/1078-0432.CCR-20-4092
Published: 15 May 2021
View article titled, The State of Melanoma: Emergent Challenges and Opportunities
Open the PDF for The State of Melanoma: Emergent Challenges and Opportunities in another window
Journal Articles

Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma

Miriam Ficial, Opeyemi A. Jegede, Miriam Sant'Angelo, Yue Hou, Abdallah Flaifel, Jean-Christophe Pignon, David A. Braun, Megan Wind-Rotolo, Maura A. Sticco-Ivins, Paul J. Catalano, Gordon J. Freeman, Arlene H. Sharpe, F. Stephen Hodi, Robert J. Motzer, Catherine J. Wu, Michael B. Atkins, David F. McDermott, Sachet A. Shukla, Toni K. Choueiri, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1371–1380.
https://doi.org/10.1158/1078-0432.CCR-20-3084
Published: 01 March 2021
View article titled, Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma
Open the PDF for Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop

Kristen L. Mueller, Marc R. Theoret, Steven J. Lemery, Laleh Amiri-Kordestani, Charlotte E. Ariyan, Michael B. Atkins, Donald A. Berry, Christian U. Blank, Angela M. DeMichele, Patrick M. Forde, Nageatte Ibrahim, Patricia Keegan, Tara C. Mitchell, Rebecca A. Moss, Caroline Robert, Rajeshwari Sridhara, Janis M. Taube, Michael T. Tetzlaff, Jennifer A. Wargo, Keith T. Flaherty, Michael J. Kaplan, Suzanne L. Topalian, Ashley F. Ward, Marc S. Hurlbert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (2): 394–401.
https://doi.org/10.1158/1078-0432.CCR-20-3285
Published: 19 January 2021
View article titled, Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop
Open the PDF for Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop in another window
Journal Articles

Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma

Jean-François Martini, Elizabeth R. Plimack, Toni K. Choueiri, David F. McDermott, Igor Puzanov, Mayer N. Fishman, Daniel C. Cho, Ulka Vaishampayan, Bradley Rosbrook, Kathrine C. Fernandez, Jamal C. Tarazi, Saby George, Michael B. Atkins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5598–5608.
https://doi.org/10.1158/1078-0432.CCR-20-1408
Published: 02 November 2020
View article titled, Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Open the PDF for Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

Matteo S. Carlino, Alexander M. Menzies, Victoria Atkinson, Jonathan S. Cebon, Michael B. Jameson, Bernard M. Fitzharris, Catriona M. McNeil, Andrew G. Hill, Antoni Ribas, Michael B. Atkins, John A. Thompson, Wen-Jen Hwu, F. Stephen Hodi, Alexander D. Guminski, Richard Kefford, Haiyan Wu, Nageatte Ibrahim, Blanca Homet Moreno, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5086–5091.
https://doi.org/10.1158/1078-0432.CCR-20-0177
Published: 01 October 2020
View article titled, Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B
Open the PDF for Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B in another window
Includes: Supplementary data
Journal Articles

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma

Michael B. Atkins, Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Cristina Suarez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Howard Gurney, Stephane Oudard, Motohide Uemura, Elaine T. Lam, Carsten Grüllich, Caroleen Quach, Susheela Carroll, Beiying Ding, Qian (Cindy) Zhu, Elisabeth Piault-Louis, Christina Schiff, Bernard Escudier
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2506–2514.
https://doi.org/10.1158/1078-0432.CCR-19-2838
Published: 01 June 2020
View article titled, Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Open the PDF for Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma

Wenxin Xu, Maneka Puligandla, Judith Manola, Andrea J. Bullock, Daniel Tamasauskas, David F. McDermott, Michael B. Atkins, Naomi B. Haas, Keith Flaherty, Robert G. Uzzo, Janice P. Dutcher, Robert S. DiPaola, Rupal S. Bhatt
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6098–6106.
https://doi.org/10.1158/1078-0432.CCR-19-0818
Published: 15 October 2019
View article titled, Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma
Open the PDF for Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma

Daniel C. Cho, Matthew B. Cohen, David J. Panka, Michael Collins, Musie Ghebremichael, Michael B. Atkins, Sabina Signoretti, James W. Mier
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (13): 4194.
https://doi.org/10.1158/1078-0432.CCR-19-1601
Published: 01 July 2019
View article titled, Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
Open the PDF for Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma in another window
Journal Articles

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Jean-Christophe Pignon, Opeyemi Jegede, Sachet A. Shukla, David A. Braun, Christine E. Horak, Megan Wind-Rotolo, Yuko Ishii, Paul J. Catalano, Jonian Grosha, Abdallah Flaifel, Jesse S. Novak, Kathleen M. Mahoney, Gordon J. Freeman, Arlene H. Sharpe, F. Stephen Hodi, Robert J. Motzer, Toni K. Choueiri, Catherine J. Wu, Michael B. Atkins, David F. McDermott, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2174–2184.
https://doi.org/10.1158/1078-0432.CCR-18-3206
Published: 01 April 2019
View article titled, irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Open the PDF for irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study

Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, Deborah J. Wong, Shailender Bhatia, Marihella James, Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1805–1815.
https://doi.org/10.1158/1078-0432.CCR-17-3436
Published: 12 April 2018
View article titled, Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
Open the PDF for Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study in another window
Includes: Supplementary data
Journal Articles

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Lisa H. Butterfield, Fengmin Zhao, Sandra Lee, Ahmad A. Tarhini, Kim A. Margolin, Richard L. White, Michael B. Atkins, Gary I. Cohen, Theresa L. Whiteside, John M. Kirkwood, David H. Lawson
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5034–5043.
https://doi.org/10.1158/1078-0432.CCR-16-3016
Published: 31 August 2017
View article titled, Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)
Open the PDF for Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697) in another window
Includes: Supplementary data
Journal Articles

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Martin H. Voss, Rupal S. Bhatt, Elizabeth R. Plimack, Brian I. Rini, Robert S. Alter, J. Thaddeus Beck, Dawn Wilson, Xiaosha Zhang, Musa Mutyaba, Chad Glasser, Kenneth M. Attie, Matthew L. Sherman, Shuchi S. Pandya, Michael B. Atkins
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3557–3565.
https://doi.org/10.1158/1078-0432.CCR-16-2395
Published: 13 July 2017
View article titled, The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Open the PDF for The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

Naomi B. Haas, Judith Manola, Bonnie Ky, Keith T. Flaherty, Robert G. Uzzo, Christopher J. Kane, Michael Jewett, Lori Wood, Christopher G. Wood, Michael B. Atkins, Janice J. Dutcher, George Wilding, Robert S. DiPaola
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (18): 4048–4054.
https://doi.org/10.1158/1078-0432.CCR-15-0215
Published: 14 September 2015
View article titled, Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805
Open the PDF for Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805 in another window
Includes: Supplementary data
Journal Articles

Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer

Liang Zhang, Xiaoen Wang, Andrea J. Bullock, Marcella Callea, Harleen Shah, Jiaxi Song, Kelli Moreno, Barbara Visentin, Douglas Deutschman, David C. Alsop, Michael B. Atkins, James W. Mier, Sabina Signoretti, Manoj Bhasin, Roger A. Sabbadini, Rupal S. Bhatt
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1925–1934.
https://doi.org/10.1158/1078-0432.CCR-14-2031
Published: 14 April 2015
View article titled, Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer
Open the PDF for Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer in another window
Includes: Supplementary data
Journal Articles

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

David F. McDermott, Su-Chun Cheng, Sabina Signoretti, Kim A. Margolin, Joseph I. Clark, Jeffrey A. Sosman, Janice P. Dutcher, Theodore F. Logan, Brendan D. Curti, Marc S. Ernstoff, Leonard Appleman, Michael K.K. Wong, Nikhil I. Khushalani, Leslie Oleksowicz, Ulka N. Vaishampayan, James W. Mier, David J. Panka, Rupal S. Bhatt, Alexandra S. Bailey, Bradley C. Leibovich, Eugene D. Kwon, Fairooz F. Kabbinavar, Arie S. Belldegrun, Robert A. Figlin, Allan J. Pantuck, Meredith M. Regan, Michael B. Atkins
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (3): 561–568.
https://doi.org/10.1158/1078-0432.CCR-14-1520
Published: 01 February 2015
View article titled, The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma in another window